Actualités et vidéos - CYTOSORBENTS CORP.

CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit PR Newswire PRINCETON, N.J., March 21, 2025 The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024 , and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025 PRINCETON, N.J. , March 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO PR Newswire NEW YORK, Jan. 30, 2024 NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Cytosorbents and certain of...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO PR Newswire NEW YORK, Jan. 22, 2024 NEW YORK , Jan. 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Cytosorbents and certain of...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO PR Newswire NEW YORK, Jan. 14, 2024 NEW YORK , Jan. 14, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Cytosorbents and certain of...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO PR Newswire NEW YORK, Jan. 6, 2024 NEW YORK , Jan. 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Cytosorbents and certain of...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO PR Newswire NEW YORK, Dec. 29, 2023 NEW YORK , Dec. 29, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Cytosorbents and certain of...

Thinking about buying stock in Macy's Inc, Altamira Therapeutics, Neurosense Therapeutics, Cytosorbents, or Designer Brands? PR Newswire NEW YORK, Dec. 5, 2023 NEW YORK , Dec. 5, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for M, CYTO, NRSN, CTSO, and DBI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. M:...

CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial PR Newswire PRINCETON, N.J., Aug. 14, 2023 Readout of topline results expected before year-end on FDA Breakthrough Device, DrugSorb-ATR. Sets stage for potential regulatory submission to FDA and Health Canada as the first reversal agent for the blood thinner, Brilinta ® PRINCETON, N.J. , Aug. 14, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care...

CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference PR Newswire PRINCETON, N.J., Feb. 27, 2023 PRINCETON , N.J. , Feb. 27, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan , Chief Executive Officer, will present at the Cowen 43 rd Annual Health Care Conference at the Boston Marriott Copley Place, in...

CytoSorbents to Report Fiscal 2022 Operating and Financial Results PR Newswire MONMOUTH JUNCTION, N.J., Feb. 24, 2023 MONMOUTH JUNCTION, N.J. , Feb. 24, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2022 financial results on Thursday, March 9, 2023 at 4:30PM EST . CytoSorbents' management will host a live conference call and...

CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue PR Newswire PRINCETON, N.J., Jan. 31, 2023 Cumulative CytoSorb treatments surpassed 195,000. Q4 2022 product sales rebounded from Q3 2022 low. Adjusted for constant currency, Core non-COVID 2022 product sales were within 5% of that achieved in 2021 and greater than 30% increased from pre-pandemic 2019 PRINCETON, N.J. , Jan. 31, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a...

CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial PR Newswire PRINCETON, N.J., Jan. 23, 2023 PRINCETON, N.J. , Jan. 23, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has received regulatory approval from Health Canada allowing inclusion of Canadian sites...

CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs PR Newswire PRINCETON, N.J., Jan. 17, 2023 Dr. Irina Kulinets , seasoned U.S. and international medical device regulatory expert, joins CytoSorbents' executive management team to lead FDA marketing approval of DrugSorb®-ATR and other global regulatory priorities PRINCETON, N.J. , Jan. 17, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening...

CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement PR Newswire PRINCETON, N.J., Dec. 29, 2022 Non-dilutive debt capital at market favorable terms strengthens the balance sheet and provides additional working capital to fund key clinical and commercial initiatives PRINCETON, N.J. , Dec. 29, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...

CytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without Modifications PR Newswire PRINCETON, N.J., Dec. 21, 2022 PRINCETON, N.J. , Dec. 21, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has received the...

CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled PR Newswire PRINCETON, N.J., Nov. 14, 2022 PRINCETON, N.J. , Nov. 14 , 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that 40 of the targeted 120 patients have been enrolled in the S afe and T imely A...

CytoSorbents Reports Third Quarter 2022 Financial and Operational Results PR Newswire PRINCETON, N.J., Nov. 3, 2022 CytoSorbents expects to achieve first milestone of the U.S. pivotal STAR-T Trial this month PRINCETON, N.J. , Nov. 3, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported unaudited...

'Enhanced Lung Rest' with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals PR Newswire PRINCETON, N.J., Nov. 2, 2022 90-day survival was 74% overall, with early intervention with ECMO and CytoSorb associated with improved survival, and shorter duration on ECMO, mechanical ventilation, and ICU stay compared to late intervention PRINCETON, N.J. , Nov. 2, 2022 /PRNewswire/ -- CytoSorbents Corporation...

National Institutes of Health Grants Phase I SBIR Award to CytoSorbents to Test Novel Polymers for Cytokine and Endotoxin Removal from Septic Porcine Plasma PR Newswire PRINCETON, N.J., Oct. 31, 2022 Goal is to advance new combined blood purification technologies to treat Gram negative sepsis – a deadly global killer PRINCETON, N.J. , Oct. 31, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and...

CytoSorbents to Report Third Quarter 2022 Operating and Financial Results PR Newswire PRINCETON, N.J., Oct. 27, 2022 PRINCETON, N.J. , Oct. 27, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2022 operating and financial results after the market close on Thursday, November 3, 2022 . CytoSorbents' management will host a live...